Dementia and Alzheimer Disease

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 26, 2023.

Using trials selected by amyloid positivity, amyloid-targeting therapies had slightly greater efficacy in APOE ε4 carriers than in noncarriers.

Robust, sustained reductions in key pharmacodynamic biomarker were observed; however, this did not lead to functional benefits on any of the scales used in the trial.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep and sleep disorders.

Neurology News Network for the week ending May 20, 2023. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 19, 2023.

Neurological rehabilitation, or neurorehabilitation, can be described as the use of rehabilitation interventions to improve or maintain function and quality of life in the context of neurological conditions.

Over a 4-month treatment period, the agent was well tolerated, with patients showing no significant changes in ADAS-Cog or CDR-SB scores, indicating no cognitive decline.

Regardless of highly different demographics and smaller sample size, the association between amyloid in the brain and plasma was influenced by overall vascular risk score, and was only consistently observed in APOE ɛ4 carriers.

Here's some of what is coming soon to NeurologyLive® this week.

At the 2023 AAN Annual Meeting, the chief medical officer at Athira Pharma spoke about findings from a phase 2 trial in which various biomarkers related to neurodegeneration showed significant improvements. [WATCH TIME: 4 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

Positive associations between preexisting obstructive sleep apnea and probable post-acute sequelae among adults were attenuated but remained significant after adjusting for other comorbidities.

Neurology News Network for the week ending May 13, 2023. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 12, 2023.

Taken together, the findings added to the growing evidence that widespread immunological and autonomic nervous system changes may contribute to long COVID.

The approval was based on 2, positive phase 3 studies in which brexpiprazole-treated patients demonstrated a 31% greater reduction in frequency of agitation symptoms vs those on placebo.

Findings showed that obstructive sleep apnea can cause early cognitive decline in middle-aged men even if they are healthy and nonobese.

The chief scientific officer at Alzheon provided insight on the preliminary imaging findings of patients enrolled in the phase 3 APOLLOE4 study assessing ALZ-801 as a potential treatment for Alzheimer disease. [WATCH TIME: 3 minutes]

In transgenic mouse models, treatment with PMN310 resulted in preserved memory, to the extent that treated mice were indistinguishable from non-transgenic control mice.

Poor higher order vision at baseline was associated with worsening cognition and increased probability of death, dementia, or frailty over 3 years.

The assistant professor in the department of neurology at the Albert Einstein College of Medicine and Montefiore Medical Center talked about predictive models in Alzheimer disease for clinical trials. [WATCH TIME: 5 minutes]

Digital technologies like the DCTclock are revolutionizing the way clinicians across all specialties can quickly assess for cognitive decline, an issue in today's aging society.

Here's some of what is coming soon to NeurologyLive® this week.